Renal Cancer - Results from #400

Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer. April 23, 2024

Avoiding "Needless" nephrectomy: What is the role of small renal mass biopsy in 2024? April 23, 2024

Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis. April 23, 2024

Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibito April 22, 2024

Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. April 22, 2024

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. April 19, 2024

Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. April 19, 2024

Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27. April 19, 2024

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma. April 18, 2024

VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. April 18, 2024

The vasculogenic mimicry related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma. April 17, 2024

Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study. April 17, 2024

Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring. April 16, 2024

NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. April 16, 2024

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). April 15, 2024

The impact of the COVID-19 pandemic on renal cancer care. April 15, 2024

Clinical safety and efficacy of microwave ablation for small renal masses. April 12, 2024

Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma. April 12, 2024

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update. April 11, 2024

Conversion to Radical Nephrectomy From Robotic Partial Nephrectomy Is Most Commonly Due to Anatomic and Oncologic Complexity. April 11, 2024

Page 21 of 456